Assess whether a CMO finding is a delay or a refuse-to-file risk (1de660)

Situation

After an FAERS cluster in a demographic the trials under-enrolled, advisory-committee question list that exposes a weak secondary endpoint is what pharmacovigilance medical reviewer can touch in a mid-size sponsor after a complete response letter. Pharma & Life Sciences will live with A CMO finding is a delay versus A refuse-to-file risk on this CMC and Development Pathways file.

Decision

Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose A CMO finding is a delay / A refuse-to-file risk using advisory-committee question list that exposes a weak secondary endpoint after an FAERS cluster in a demographic the trials under-enrolled.

Hypotheses to test

• Pharmacovigilance medical reviewer can defend A CMO finding is a delay from advisory-committee question list that exposes a weak secondary endpoint after an FAERS cluster in a demographic the trials under-enrolled in a Pharma & Life Sciences challenge.
• Pharmacovigilance medical reviewer cannot defend A CMO finding is a delay from advisory-committee question list that exposes a weak secondary endpoint; A refuse-to-file risk is what the extract actually supports after an FAERS cluster in a demographic the trials under-enrolled.
• An FAERS cluster in a demographic the trials under-enrolled never reached the population in advisory-committee question list that exposes a weak secondary endpoint — reopen intake, do not close a CMO finding is.
• Two facts in advisory-committee question list that exposes a weak secondary endpoint after an FAERS cluster in a demographic the trials under-enrolled conflict for pharmacovigilance medical reviewer; hold this CMC and Development Pathways file.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim pharmacovigilance medical reviewer would keep.
• For this Pharma & Life Sciences CMC and Development Pathways file, read advisory-committee question list that exposes a weak secondary endpoint against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move a CMO finding is for pharmacovigilance medical reviewer.